New research uncovers hidden risks and surprising benefits of weight loss drugs like Ozempic, reshaping how we see these ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

American host and television producer Oprah Winfrey recently shared her initial experience of taking the weight loss drug GLP ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

They're known to aid in blood sugar control and, now, weight loss — but, according to a sweeping new study, the popular GLP-1 ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

Hims & Hers’ decision to advertise at the Super Bowl represents an ambitious play for the brand as it positions itself in the ...

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.